Covid-19

#ABPI #Big pharma #Biopharma #Covid-19 #Ipsos #UK

Pharma maintains high level of trust from UK public and doctors

The pharmaceutical industry continues to maintain strong levels of public trust and favourability in the UK, according to data from the Association of the British Pharmaceutical Industry (ABPI). Opinions showed consistent recognition of the sector’s support for the NHS, with 67% of respondents saying the industry… Read More

#News

RNA
#Covid-19 #RNA #RNA sequencing #Roundtable

Exclusive roundtable on the delivery of RNA therapeutics

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

RNA
#Covid-19 #RNA #RNA sequencing #Roundtable

What are some of the biggest challenges related to the development & delivery of RNA therapeutics?

In this roundtable, moderated by DDW and sponsored by Azenta Life Sciences, learn about the biggest challenges related to the delivery of RNA therapeutics. Roundtable panellists include Dr Philip Cruz, UK Medical Director, Moderna, Dr Neill Liptrott, Reader in Pharmacology and Immuno-compatability, University of Liverpool, and Reece Armstrong, Editor, DDW. Read More

Webinar date:
Sponsored by Azenta Life Sciences
#Webinars

Preparing Covid-19 vaccine for injection
#BioNTech #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Moderna #Novavax #Pfizer #Vaccines

New Covid-19 vaccines ready to slow spread of EG.5

It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 strain. EG.5 or ‘Eris’ has been found in more than 50 countries. It is the most common and fastest growing Covid-19 subvariant in the US, estimated… Read More

#News #Trending News

Covid-19
#Antivirals #Covid-19 #Covid-19 treatment #Infex Therapeutics #Preclinical investigations

New antiviral potential solution to resistant Covid-19 variants

In preclinical studies, a new pan-coronavirus papain-like protease (PLpro) inhibitor has shown a near complete reduction in SARS-CoV-2 viral load in the lungs. Infex Therapeutics has selected the clinical candidate for its in-house COV-X programme based on this in vivoefficacy data in a murine SARS-CoV-2 model. Read More

#News #Trending News

Vaccine research
#Covid-19 #Disease X #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #UK

UK vaccine centre offers opportunity for pandemic preparedness

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘Disease X‘, a term used because what might trigger the next pandemic is unknown. Read More

#News #Trending News

Vaccine
#Covid booster #Covid-19 #HIPRA Human Health #Immunology / Virology & Vaccines #MHRA

Bimervax Covid-19 vaccine authorised in UK

Bimervax from HIPRA Human Health has been authorised in the UK after meeting the Medicines & Healthcare products Regulatory Agency’s (MHRA) required safety, quality and effectiveness standards. It becomes the ninth Covid-19 vaccine to be authorised by the UK’s independent medicines regulator. Bimervax combines… Read More

#News

Drug discovery illustration
#Covid-19 #Drug repositioning #Drug repurposing #Events #Paediatrics #Pharmacology #Rare disease #World Congress of Basic & Clinical Pharmacology

Drug repurposing: The benefits, risks and what we learned from Covid-19

What are benefits of drug repurposing and why do clinical drug trials so often fail? Diana Spencer summarises the key messages from the ‘Drug Repurposing: Challenges and Opportunities’ Symposium held at the 19th World Congress of Basic & Clinical Pharmacology (WCP) 2023. The Drug Repurposing symposium at WCP 2023 was… Read More

#Exclusive Content

Long Covid
#Chronic Fatigue Syndrome #Covid-19 #Genetic profiling #Genetics / genomics #Long Covid

Ground-breaking study identifies novel drug targets for long Covid

A study into long Covid has provided the first detailed genetic insights into the condition and its commonalities with other diseases, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Despite considerable global research, studies have so far failed to identify the detailed genetic risk factors for long Covid,… Read More

#News #Trending News

#AMR #Covid-19 #Diabetes #Drug development #FDA #Genetics / genomics #Influenza #Parasitic disease

New DDW Highlights podcast: 10 July 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial… Read More

#News

#AMR #Covid-19 #Diabetes #Drug development #FDA #Genetics / genomics #Influenza #Parasitic disease

This week in drug discovery (3-7 July)  

News round-up for 3-7 July by DDW Digital Content Editor Diana Spencer. It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial of datopotamab deruxtecan did not meet its second primary endpoint and saw an 8% drop in its stock… Read More

#News

Antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Covid-19 #Gut microbiome

Severe Covid-19 linked to antibiotics overuse

Frequent and diverse use of antibiotics may be associated with developing more severe outcomes after a Covid-19 infection, including death, UK scientists have shown. The findings, funded by Health Data Research UK and the National Institute for Health and Care Research (NIHR), act as a warning… Read More

#Editor's Choice #News

#Animal models #Cancer immunotherapy #Cell therapy #Covid-19 #Humanised Immune System (HIS) #Immunotherapy #Monoclonal antibodies #Mouse models #Oncology #Regulatory

Podcast: Immunotherapy, avelumab and the immunocompromised

This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “… Read More

#News

#AI / data analytics / healthtech / informatics #Covid-19 #Genomics #Machine learning #Microfluidics

New podcast: Reaching new heights with drug discovery

This is the latest episode of the free DDW narrated podcast, “Reaching new heights with drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “High-throughput technologies: Reaching for the stars” and “… Read More

#News

Hospital patient on ventilator
#Covid-19 #Covid-19 treatment #InflaRx #United States

InflaRx launches emergency Covid-19 treatment in the US

Biopharmaceutical company InflaRx has launched Gohibic (vilobelimab) in the US for the treatment of Covid-19. In April 2023, Gohibic was granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) in hospitalised adults when initiated within 48 hours of… Read More

#News

UK
#Covid-19 #Global data #Life sciences #Pharmaceutical industry #World

More trust for pharma in the UK than the US

Six out of 10 people in the UK trust pharma businesses to do what is right: up 1% on last year. The UK places more trust in pharma than European neighbours France (52%), Germany (55%), or the industry’s largest global market, the US (54%). Read More

#News